coronary heart disease
Conditions
Interventions
Experimental group:Yuekang Huoxin Pills (concentrated pills) 2 pills at a time, 3 times a day
Control group:Yuekang Huoxin Pills (concentrated pills) simulant 2 pills at a time, 3 times a day
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years; 2. Patients who meet the diagnostic criteria of Western medicine for coronary heart disease, elective patients within two weeks after DCB surgery, including patients with primary large-vessel lesions or in-stent restenosis; 3.Meet the TCM criteria for syndrome differentiation of Qi deficiency and blood stasis (total score >= 8 points, and secondary symptoms >= 4 points); 4. The patients voluntarily participated in the trial and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe arrhythmia, severe cardiopulmonary insufficiency and poorly controlled hypertension; 2. Patients with serious primary diseases such as severe liver and kidney damage, hematopoietic system, and mental illness; 3. Patients with heart valve disease, cardiomyopathy, congenital heart disease, aortic dissection or aortic aneurysm that need to be corrected by surgery or interventional therapy; 4. Patients with acute myocardial infarction, stroke and transient ischemic attack within 6 months; 5. Pregnant, planning pregnancy or lactating patients; 6. Allergic constitution and those who are allergic to known components of the research drug; 7. Those who are participating in other clinical trials or have participated in other drug clinical trials within one month; 8. Those who are judged by the investigator to be unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| quantitative flow fraction (QFR) values at 12-month postoperative follow-up; | — |
Secondary
| Measure | Time frame |
|---|---|
| quantitative flow fraction (QFR) change values;late lume loss;binary restenosis;diameter stenosis;incidence of revascularization;incidence of cardiovascular composite endpoints;incidence of main adverse cardiac events composite endpoints;TCM syndrome scale; | — |
Countries
China
Contacts
Public ContactMa Lihong
Fuwai Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed